
Imunon, Inc. (NASDAQ:IMNN – Free Report) – Equities research analysts at Brookline Capital Markets upped their FY2026 EPS estimates for shares of Imunon in a note issued to investors on Friday, November 13th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will earn ($2.74) per share for the year, up from their previous estimate of ($2.89). The consensus estimate for Imunon’s current full-year earnings is ($2.68) per share. Brookline Capital Markets also issued estimates for Imunon’s Q4 2026 earnings at ($0.73) EPS, Q1 2027 earnings at ($0.69) EPS, Q2 2027 earnings at ($0.67) EPS, Q3 2027 earnings at ($0.67) EPS, Q4 2027 earnings at ($0.65) EPS and FY2027 earnings at ($2.67) EPS.
Imunon (NASDAQ:IMNN – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.09).
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Imunon in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $10.00.
View Our Latest Research Report on Imunon
Imunon Stock Performance
Shares of NASDAQ IMNN opened at $0.59 on Tuesday. Imunon has a 1 year low of $0.49 and a 1 year high of $4.35. The company’s 50-day moving average is $1.13 and its 200 day moving average is $2.09. The company has a current ratio of 1.82, a quick ratio of 1.82 and a debt-to-equity ratio of 2.86.
About Imunon
Imunon, Inc. is a clinical-stage biotechnology company developing treatments for cancer. Formerly known as Celsion Corporation, the company adopted the Imunon name in 2022 and is based in Lawrenceville, New Jersey. Its lead candidate, IMNN-001 (formerly GEN-1), is an investigational DNA-based immunotherapy designed to prompt local production of interleukin-12, a protein that can stimulate an immune response against tumors. Imunon is studying the treatment in combination with chemotherapy for newly diagnosed advanced ovarian cancer.
Further Reading
- Five stocks we like better than Imunon
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
